药品首页 >
DTP药房
专病产品 > 高血糖
全球品牌 > 武田/Takeda
日本直供

Zafatek 琥珀酸曲格列汀片

通用名称琥珀酸曲格列汀片 Trelagliptin succinate
品牌名称Zafatek
产地|公司日本(Japan) | 武田(Takeda)
技术状态原研产品
成分|含量100mg
包装|存储4片/盒 室温
微信客服
Xirou_Canada
微信ID
(8:00-15:00)
服务时间
通用中文 琥珀酸曲格列汀片 通用外文 Trelagliptin succinate
品牌中文 品牌外文 Zafatek
其他名称
公司 武田(Takeda) 产地 日本(Japan)
含量 100mg 包装 4片/盒
剂型给药 片剂口服 储存 室温
适用范围 用于2型糖尿病的治疗
通用中文 琥珀酸曲格列汀片
通用外文 Trelagliptin succinate
品牌中文
品牌外文 Zafatek
其他名称
公司 武田(Takeda)
产地 日本(Japan)
含量 100mg
包装 4片/盒
剂型给药 片剂口服
储存 室温
适用范围 用于2型糖尿病的治疗

使用说明书

(免责声明:本说明书仅供参考,不作为治疗的依据,不可取代任何医生、药剂师等专业性的指导。本站不提供治疗建议,药物是否适合您,请专业医生(或药剂师)决定。)
等待内容更新

中文说明

(免责声明:本说明书仅供参考,不作为治疗的依据,不可取代任何医生、药剂师等专业性的指导。本站不提供治疗建议,药物是否适合您,请专业医生(或药剂师)决定。)

英文药名:Zafatek(Trelagliptin succinate Tablets)

中文药名:琥珀酸曲格列汀片

生产厂家:武田制药

ザファテック錠100mg/ザファテック錠50mg 

治疗类别名称
可持续性选择性DPP-4抑制剂
-2型糖尿病治疗药物-
上市时间:2015年3月7日(日本)
商標名 
Zafatek Tablets 
化学構造式

一般名 
トレラグリプチンコハク酸塩(Trelagliptin Succinate)〔JAN〕 
化学名 
2-({6-[(3R)-3-Aminopiperidin-1-yl]-3-methyl-2, 4-dioxo-3, 4- dihydropyrimidin -1(2H)-yl} methyl)-4-fluorobenzonitrile monosuccinate 
分子式 
C18H20FN5O2・C4H6O4 
分子量 
475.47 
融点 
187.1℃ 
性状 
Zafatek是一种白色或类白色结晶或结晶性粉末。水或易溶于二甲基亚砜,难溶于甲醇,乙醇(99.5),微溶于四氢呋喃或二乙胺,在乙腈或2-丙醇非常微溶。
条件批准
在建立药品风险管理计划的顶部,要正确实施。
药效药理
1. 作用机序
通过这种药物以抑制二肽基肽-4(DPP-4)灭活从肠道分泌的胰高血糖素样肽进入血液通过口服摄取刺激选项-1(GLP-1),GLP的活性-1的血液水平升高促进从糖浓度依赖性的胰腺胰岛素分泌。
2. 药理作用
(1) DPP-4抑制效果
1) 选择性抑制人血浆DPP-4活性(IC 50值:4.2nmol/L)体外。此外,为了比较Toreraguripuchin和阿格列汀的DPP-4抑制活性,比较在相同的条件(体外)下的IC 50值和(纳摩尔/升),分别为1.3和5.3。
2) 饮食,运动疗法之间为100毫克作为Toreraguripuchin的12周口服给药用于治疗2型糖尿病也血糖控制不充分进行(一周一次早餐前)为安慰剂对照,双盲,平行组比较研究在,在最后一次给药的平均值7天DPP-4活性抑制率后是Toreraguripuchin100毫克组中的77.4%。
(2) 活性GLP-1浓度的增加作用
饮食,运动疗法之间为100毫克作为Toreraguripuchin的12周口服给药用于治疗2型糖尿病也血糖控制不充分进行(一周一次早餐前)为安慰剂对照,双盲,平行组比较研究在,在12个星期后,膳食耐受性测试活性GLP-1浓度被显著增加相比,安慰剂组为。
(3) 耐糖能改善作用
和Toreraguripuchin的单剂量口服过夜禁食肥胖2型糖尿病模型(威斯特肥鼠)和非肥胖2型糖尿病模型(N- STZ-1.5只大鼠),葡萄糖耐受性试验,其葡萄糖施用后口服给药1小时在葡萄糖耐受性的改善作用进行了观察。
适应病症
用于2型糖尿病的治疗 
用法用量
口服,每周一次,每次100mg


製造販売元 
武田薬品工業株式会社

 

外文说明

(免责声明:本说明书仅供参考,不作为治疗的依据,不可取代任何医生、药剂师等专业性的指导。本站不提供治疗建议,药物是否适合您,请专业医生(或药剂师)决定。)

Description

This medicine inhibits DPP-4, an enzyme degrading incretin hormones that maintain a constant level of blood glucose, to stimulate insulin secretion when blood glucose is elevated and thereby to improve blood glucose control.
It is usually used to treat type II diabetes mellitus.

Presentation

4 tablets

Feature

Pale red oval tablet

Active Ingredients

Trelagliptin succinate

Effect/Efficacy

This medicine inhibits DPP-4, an enzyme degrading incretin hormones that maintain a constant level of blood glucose, to stimulate insulin secretion when blood glucose is elevated and thereby to improve blood glucose control.
It is usually used to treat type II diabetes mellitus.

Usage/Dosage

In general, for adults, take 1 tablet (100 mg of trelagliptin) at a time, once a week, on a fixed day of the week. The dosage may be reduced according to the degree of renal function in patients with moderate renal dysfunction. Strictly follow the instructions.
If you miss a dose, take the missed dose as soon as possible and then follow your regular weekly dosing schedule. You should never take two doses at one time.
If you accidentally take more than your prescribed dose, consult with your doctor or pharmacist.
Do not stop taking this medicine unless your doctor instructs you to do so.

Cautions

Before using this medicine, be sure to tell your doctor and pharmacist :
If you have previously experienced any allergic reactions (itch, rash, etc.) to any medicines.
If you have ketosis, diabetic coma or precoma, type 1 diabetes mellitus, severe infection, an injury, renal disorder, pituitary abnormality or adrenal disease.
If you are in a pre- or post-operative status or weakened.
If you do not consume an adequate diet.
If you have been doing vigorous exercise or taking a large amount of alcohol.
If you are pregnant or breastfeeding.
If you are taking any other medicinal products. (Some medicines may interact to enhance or diminish medicinal effects. Beware of over-the-counter medicines and dietary supplements as well as other prescription medicines.)

Contraindication

The most commonly reported adverse reactions include nasopharyngitis, rash and itching. If any of these symptoms occur, consult with your doctor or pharmacist.
The symptoms described below are rarely seen as initial symptoms of the adverse reactions indicated in brackets. If any of these symptoms occur, stop taking this medicine and see your doctor immediately.
- cold sweat, hungry feeling, trembling of limbs [hypoglycemia]
The above symptoms do not describe all the adverse reactions to this medicine. Consult with your doctor or pharmacist if you notice any symptoms of concern other than those listed above.